In the largest cohort of CRC patients (>36,000 patients) reported to date [20], no significant differences were found regarding KRAS and NRAS mutations, although EOCRC patients were significatively less likely to present BRAF V600E mutations than later-onset CRC patients (5% vs. 10%; p < 0.001). Here, KRAS is linked to colorectal carcinoma.